Harbour BioMed has transitioned from a traditional licensor to a significant shareholder in Spruce Biosciences, exercising warrants to acquire a nearly 4% stake in the California-based rare disease specialist.
Sila Realty Trust (NYSE:SILA) completed the $43.1 million acquisition of the Nobis OKC Facility on Friday, a move that underscores the REIT’s strategy of targeting market-dominant healthcare assets with high occupancy and limited competition.
ImmunityBio (NASDAQ:IBRX) announced on Friday that its mission to redefine the first-line treatment for bladder cancer is moving faster than anticipated, putting a critical regulatory filing within reach for late 2026.
Axsome Therapeutics (NASDAQ:AXSM) announced on Thursday that it has dosed the first patient in its FORWARD Phase 3 clinical trial, a pivotal step in the development of AXS-14 (esreboxetine) for the management of fibromyalgia.
Neurocrine Biosciences (NASDAQ:NBIX) presented the first head-to-head imaging data on Thursday comparing the brain-binding potency of the two leading treatments for involuntary movement disorders.
Hoth Therapeutics (NASDAQ:HOTH) announced Thursday that it has received a positive regulatory conclusion under the European Union Clinical Trials Information System (CTIS) for Part I of its HT-001 clinical program.
Beam Therapeutics (NASDAQ:BEAM) bolstered its position as a leader in the genetic medicine space on Thursday, reporting a formidable cash pile of $1.1 billion as of September 30, 2025.
Boston Scientific Corp. (NYSE:BSX) announced a definitive agreement on Thursday to acquire Penumbra (NYSE:PEN) in a cash-and-stock transaction valuing the company at $374 per share, or an enterprise value of approximately $14.5 billion.
Aurora Cannabis (NASDAQ:ACB) has entered the final stage of production trials for a new generation of cannabis cultivars designed to be naturally immune to powdery mildew, a breakthrough that could eliminate one of the industry's most expensive cultivation risks.
Intuitive Surgical (NASDAQ:ISRG) hit a major financial landmark Wednesday, reporting preliminary 2025 revenue of $10.06 billion, a 21% increase over the prior year.
The results, fueled by the rapid rollout of the next-generation da Vinci 5 system, underscore the company’s dominant grip on the robotic-assisted surgery market as it transitions from a niche technology provider to a foundational healthcare infrastructure giant.
ImmunityBio (NASDAQ:IBRX) announced Wednesday that the Saudi Food and Drug Authority (SFDA) has approved ANKTIVA® (nogapendekin alfa inbakicept) for the treatment of non-muscle invasive bladder cancer (NMIBC).
Dr. Reddy’s Laboratories (NYSE:RDY) announced Wednesday the first-to-market launch of its over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution, 0.7%, providing a lower-cost generic equivalent to Alcon’s Extra Strength Pataday® Once-Daily Relief.
